US Stock MarketDetailed Quotes

ArriVent BioPharma (AVBP)

Watchlist
  • 30.540
  • +0.340+1.13%
Close Jun 12 16:00 ET
  • 30.540
  • 0.0000.00%
Post 16:10 ET
1.42BMarket Cap-9.04P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

ArriVent BioPharma (AVBP) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-30.94%46.11M
88.25%177.53M
63.78%38.82M
58.12%38.32M
30.84%33.62M
222.98%66.77M
26.44%94.31M
2.54%23.71M
44.96%24.23M
13.78%25.7M
Selling and administrative expenses
54.92%8.49M
58.02%24.18M
87.69%6.65M
48.38%6.15M
50.63%5.9M
48.23%5.48M
57.68%15.3M
13.96%3.54M
70.11%4.14M
76.06%3.92M
-General and administrative expense
54.92%8.49M
58.02%24.18M
87.69%6.65M
48.38%6.15M
50.63%5.9M
48.23%5.48M
57.68%15.3M
13.96%3.54M
70.11%4.14M
76.06%3.92M
Research and development costs
-38.62%37.62M
94.11%153.35M
59.57%32.18M
60.13%32.17M
27.28%27.72M
261.05%61.29M
21.76%79M
0.76%20.16M
40.67%20.09M
6.98%21.78M
Operating profit
30.94%-46.11M
-88.25%-177.53M
-63.78%-38.82M
-58.12%-38.32M
-30.84%-33.62M
-222.98%-66.77M
-26.44%-94.31M
-2.54%-23.71M
-44.96%-24.23M
-13.78%-25.7M
Net non-operating interest income expense
17.02%2.79M
-18.77%11.23M
6.74%3.28M
-9.00%3.34M
-41.83%2.22M
-26.77%2.39M
162.89%13.82M
59.58%3.07M
58.44%3.67M
275.91%3.82M
Non-operating interest income
17.02%2.79M
-18.77%11.23M
6.74%3.28M
-9.00%3.34M
-41.83%2.22M
-26.77%2.39M
162.89%13.82M
59.58%3.07M
58.44%3.67M
275.91%3.82M
Other net income (expense)
Income before tax
32.72%-43.32M
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
Income tax
Net income
32.72%-43.32M
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
Net income continuous Operations
32.72%-43.32M
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
Minority interest income
Net income attributable to the parent company
32.72%-43.32M
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
32.72%-43.32M
-106.62%-166.31M
-72.27%-35.54M
-70.09%-34.98M
-43.54%-31.4M
-269.68%-64.39M
-16.09%-80.49M
2.64%-20.63M
-42.80%-20.56M
-1.42%-21.87M
Basic earnings per share
49.47%-0.96
-68.75%-4.32
-27.87%-0.78
-36.07%-0.83
-38.46%-0.9
-171.43%-1.9
-17.99%-2.56
8.02%-0.61
-35.36%-0.61
3.69%-0.65
Diluted earnings per share
49.47%-0.96
-68.75%-4.32
-27.87%-0.78
-36.07%-0.83
-38.46%-0.9
-171.43%-1.9
-17.99%-2.56
8.02%-0.61
-35.36%-0.61
3.69%-0.65
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -30.94%46.11M88.25%177.53M63.78%38.82M58.12%38.32M30.84%33.62M222.98%66.77M26.44%94.31M2.54%23.71M44.96%24.23M13.78%25.7M
Selling and administrative expenses 54.92%8.49M58.02%24.18M87.69%6.65M48.38%6.15M50.63%5.9M48.23%5.48M57.68%15.3M13.96%3.54M70.11%4.14M76.06%3.92M
-General and administrative expense 54.92%8.49M58.02%24.18M87.69%6.65M48.38%6.15M50.63%5.9M48.23%5.48M57.68%15.3M13.96%3.54M70.11%4.14M76.06%3.92M
Research and development costs -38.62%37.62M94.11%153.35M59.57%32.18M60.13%32.17M27.28%27.72M261.05%61.29M21.76%79M0.76%20.16M40.67%20.09M6.98%21.78M
Operating profit 30.94%-46.11M-88.25%-177.53M-63.78%-38.82M-58.12%-38.32M-30.84%-33.62M-222.98%-66.77M-26.44%-94.31M-2.54%-23.71M-44.96%-24.23M-13.78%-25.7M
Net non-operating interest income expense 17.02%2.79M-18.77%11.23M6.74%3.28M-9.00%3.34M-41.83%2.22M-26.77%2.39M162.89%13.82M59.58%3.07M58.44%3.67M275.91%3.82M
Non-operating interest income 17.02%2.79M-18.77%11.23M6.74%3.28M-9.00%3.34M-41.83%2.22M-26.77%2.39M162.89%13.82M59.58%3.07M58.44%3.67M275.91%3.82M
Other net income (expense)
Income before tax 32.72%-43.32M-106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M
Income tax
Net income 32.72%-43.32M-106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M
Net income continuous Operations 32.72%-43.32M-106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M
Minority interest income
Net income attributable to the parent company 32.72%-43.32M-106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 32.72%-43.32M-106.62%-166.31M-72.27%-35.54M-70.09%-34.98M-43.54%-31.4M-269.68%-64.39M-16.09%-80.49M2.64%-20.63M-42.80%-20.56M-1.42%-21.87M
Basic earnings per share 49.47%-0.96-68.75%-4.32-27.87%-0.78-36.07%-0.83-38.46%-0.9-171.43%-1.9-17.99%-2.568.02%-0.61-35.36%-0.613.69%-0.65
Diluted earnings per share 49.47%-0.96-68.75%-4.32-27.87%-0.78-36.07%-0.83-38.46%-0.9-171.43%-1.9-17.99%-2.568.02%-0.61-35.36%-0.613.69%-0.65
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +11.05%
Sample Name
Sample Code
 +1.03%
Sample Name
Sample Code
 -2.29%
4
VanEck Oil Services ETF
OIH
-3.00%
5
ProShares Ultra Energy
DIG
-3.15%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +12.02%
Sample Name
Sample Code
 +9.96%
Sample Name
Sample Code
 +9.80%
4
Qifu Technology
QFIN
+5.99%
5
Futu Holdings Ltd
FUTU
+5.64%
View More
Middle East conflict spreads to the stock market! How should investors respond?
The more than three-month-long U.S.-Iran war has finally come to an end! Pakistani Prime Minister Shehbaz announced on Sunday that the Unite Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -